- Home
- TEM vs ROIV Comparison
TEM vs ROIV Comparison
Compare TEM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- ROIV
- Stock Information
- Founded
- TEM 2015
- ROIV 2014
- Country
- TEM United States
- ROIV United Kingdom
- Employees
- TEM N/A
- ROIV N/A
- Industry
- TEM
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TEM
- ROIV Health Care
- Exchange
- TEM NYSE
- ROIV Nasdaq
- Market Cap
- TEM 6.3B
- ROIV 8.4B
- IPO Year
- TEM 2024
- ROIV N/A
- Fundamental
- Price
- TEM $31.83
- ROIV $10.94
- Analyst Decision
- TEM Buy
- ROIV Strong Buy
- Analyst Count
- TEM 11
- ROIV 8
- Target Price
- TEM $57.20
- ROIV $17.93
- AVG Volume (30 Days)
- TEM 4.0M
- ROIV 5.3M
- Earning Date
- TEM 02-17-2025
- ROIV 02-11-2025
- Dividend Yield
- TEM N/A
- ROIV N/A
- EPS Growth
- TEM N/A
- ROIV N/A
- EPS
- TEM N/A
- ROIV 5.89
- Revenue
- TEM $640,442,000.00
- ROIV $129,128,999.00
- Revenue This Year
- TEM $32.70
- ROIV $15.98
- Revenue Next Year
- TEM $38.77
- ROIV N/A
- P/E Ratio
- TEM N/A
- ROIV $1.86
- Revenue Growth
- TEM 32.13
- ROIV 145.68
- 52 Week Low
- TEM $22.89
- ROIV $9.69
- 52 Week High
- TEM $79.49
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- ROIV 38.75
- Support Level
- TEM N/A
- ROIV $10.42
- Resistance Level
- TEM N/A
- ROIV $11.82
- Average True Range (ATR)
- TEM 0.00
- ROIV 0.35
- MACD
- TEM 0.00
- ROIV -0.11
- Stochastic Oscillator
- TEM 0.00
- ROIV 29.21
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.